NVIDIA AI Podcast Isomorphic Labs Discusses AI-Driven Drug Discovery and the Future of Medicine - Ep. 252
124 snips
Apr 16, 2025 
Max Jaderberg and Sergei Yakneen from Isomorphic Labs share their insights on AI's game-changing role in drug discovery. Jaderberg spearheads AI model development while Yakneen navigates technology applications in healthcare. They discuss how advanced AI models like AlphaFold 3 are revolutionizing precision medicine by treating biology as an information processing system. The duo highlights the critical need for robust infrastructure, high-quality data, and innovative methods to overcome current challenges in the pharmaceutical landscape.
AI Snips
Chapters
Transcript
Episode notes
Max Jaderberg's AI Journey
- Max Jaderberg transitioned from computer vision AI research and working with DeepMind to founding Isomorphic Labs to apply deep learning to drug design.
- His passion for deep learning and desire for positive human impact motivated him to lead AI innovation in drug discovery.
Sergei Yakneen's Path to AI Drug Discovery
- Sergei Yakneen shifted from tech industries to healthcare inspired by cancer DNA sequencing challenges and did a PhD in molecular biology.
- He joined Isomorphic Labs early, captivated by the vision to revolutionize drug discovery using AI.
Generalizable AI Models Transform Drug Design
- Traditional drug discovery focuses on one target at a time with no knowledge transfer across projects.
- AI enables building generalizable models applicable to many proteins and diseases, transforming drug design into a scalable, reusable engine.